|
JP6815318B2
(ja)
|
2014-12-23 |
2021-01-20 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
二官能性分子によって標的化タンパク質分解を誘導する方法
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
AU2016232705C1
(en)
|
2015-03-18 |
2021-06-17 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
WO2017185036A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of egfr and methods of use
|
|
AU2017254702B2
(en)
*
|
2016-04-22 |
2020-12-24 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use
|
|
EP3512842B1
(en)
|
2016-09-15 |
2024-01-17 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
MX2019005007A
(es)
*
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
*
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
IL319363A
(en)
|
2017-01-31 |
2025-05-01 |
Arvinas Operations Inc |
Cervalon ligands and bifunctional compounds containing them
|
|
US12023385B2
(en)
|
2017-02-08 |
2024-07-02 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation with heterobifunctional compounds
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
CN111491933A
(zh)
*
|
2017-12-18 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
具有e3泛素连接酶部分的egfr双功能抑制剂
|
|
JP2021512059A
(ja)
|
2018-01-29 |
2021-05-13 |
ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド |
ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用方法
|
|
TW201945357A
(zh)
|
2018-02-05 |
2019-12-01 |
瑞士商赫孚孟拉羅股份公司 |
化合物
|
|
CA3090275A1
(en)
|
2018-02-14 |
2019-08-22 |
Dana-Farber Cancer Institute, Inc. |
Irak degraders and uses thereof
|
|
WO2019164945A1
(en)
*
|
2018-02-20 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Pharmaceutical combinations of egfr inhibitors and methods of use thereof
|
|
WO2019183523A1
(en)
*
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
|
US12539292B2
(en)
|
2018-04-01 |
2026-02-03 |
Arvinas Operations, Inc. |
BRM targeting compounds and associated methods of use
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CN108610332B
(zh)
*
|
2018-06-08 |
2020-04-03 |
绍兴文理学院 |
诱导MDM2自我降解E3泛素连接酶二聚体酯类小分子PROTACs
|
|
CN108610333B
(zh)
*
|
2018-06-08 |
2020-04-03 |
绍兴文理学院 |
诱导MDM2自我降解E3泛素连接酶二聚体酰胺类小分子PROTACs
|
|
WO2019241231A1
(en)
*
|
2018-06-11 |
2019-12-19 |
Abhishek Sharma |
Antiestrogen compounds
|
|
WO2020027225A1
(ja)
|
2018-07-31 |
2020-02-06 |
ファイメクス株式会社 |
複素環化合物
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
US12642856B2
(en)
|
2018-09-28 |
2026-06-02 |
Dana-Farber Cancer Institute, Inc. |
Degraders of hepatitis C virus NS3/4A protein
|
|
JP2022507267A
(ja)
|
2018-11-13 |
2022-01-18 |
バイオセリックス， インコーポレイテッド |
置換イソインドリノン
|
|
EP3932922A4
(en)
|
2019-02-25 |
2022-05-11 |
ShanghaiTech University |
SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE
|
|
EP3941607A1
(en)
|
2019-03-21 |
2022-01-26 |
Codiak BioSciences, Inc. |
Process for preparing extracellular vesicles
|
|
KR20210141554A
(ko)
|
2019-03-21 |
2021-11-23 |
코디악 바이오사이언시즈, 인크. |
세포외 소포 접합체 및 이의 용도
|
|
KR102947433B1
(ko)
|
2019-04-12 |
2026-04-06 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
CN110204532B
(zh)
*
|
2019-05-15 |
2022-03-08 |
浙江工业大学 |
一种靶向egfr蛋白降解的化合物及其制备方法和应用
|
|
AU2020298293A1
(en)
|
2019-06-21 |
2022-01-20 |
Dana-Farber Cancer Institute, Inc. |
Allosteric EGFR inhibitors and methods of use thereof
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
WO2021023233A1
(zh)
*
|
2019-08-05 |
2021-02-11 |
上海科技大学 |
Egfr蛋白降解剂及其抗肿瘤应用
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
MX2022004526A
(es)
|
2019-10-17 |
2022-07-21 |
Arvinas Operations Inc |
Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6.
|
|
KR20220114615A
(ko)
*
|
2019-12-16 |
2022-08-17 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Egfr 키나제의 분해를 억제 및 유도하는 화합물
|
|
WO2021127443A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP4681715A3
(en)
|
2019-12-20 |
2026-01-28 |
C4 Therapeutics, Inc. |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
WO2021152113A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Bayer Aktiengesellschaft |
Substituted 2,3-benzodiazepines derivatives
|
|
WO2021237100A1
(en)
|
2020-05-21 |
2021-11-25 |
Codiak Biosciences, Inc. |
Methods of targeting extracellular vesicles to lung
|
|
CN111592535B
(zh)
*
|
2020-06-22 |
2021-07-20 |
通化师范学院 |
一种抗egfr突变的抑制剂eai045的制备方法
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
CN114057770B
(zh)
*
|
2020-08-06 |
2023-05-02 |
成都先导药物开发股份有限公司 |
靶向egfr蛋白降解的双功能化合物
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CA3191532A1
(en)
*
|
2020-09-11 |
2022-03-17 |
Hyung-Chul Ryu |
Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
WO2022066928A2
(en)
|
2020-09-23 |
2022-03-31 |
Codiak Biosciences, Inc. |
Process for preparing extracellular vesicles
|
|
TW202221000A
(zh)
|
2020-09-30 |
2022-06-01 |
英屬開曼群島商百濟神州有限公司 |
用於降解ｅｇｆｒ之雙功能化合物及相關使用方法
|
|
CN112608302B
(zh)
*
|
2020-12-28 |
2022-05-24 |
郑州大学第一附属医院 |
低氧还原激活靶向泛素化降解egfr蛋白的喹唑啉类衍生物及其应用
|
|
CN116847848A
(zh)
|
2021-02-10 |
2023-10-03 |
百济神州有限公司 |
Egfr降解剂和使用方法
|
|
CN113004251B
(zh)
*
|
2021-03-05 |
2022-09-27 |
郑州大学第一附属医院 |
含2-硝基咪唑的喹唑啉类衍生物及其应用
|
|
KR20240016250A
(ko)
*
|
2021-04-02 |
2024-02-06 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
암 치료를 위한 병용요법
|
|
CN118388454A
(zh)
|
2021-04-16 |
2024-07-26 |
阿尔维纳斯运营股份有限公司 |
Bcl6蛋白水解的调节剂和其相关使用方法
|
|
US11981678B2
(en)
|
2021-04-29 |
2024-05-14 |
Northwestern University |
Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) protein
|
|
EP4330251A4
(en)
|
2021-04-30 |
2025-03-05 |
BeiGene Switzerland GmbH |
EGFR DEGRADING AGENTS AND METHODS OF USE THEREOF
|
|
US12042543B2
(en)
|
2021-04-30 |
2024-07-23 |
Northwestern University |
Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2
|
|
BR112023024507A2
(pt)
|
2021-05-26 |
2024-02-15 |
C4 Therapeutics Inc |
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
EP4395549A1
(en)
|
2021-09-01 |
2024-07-10 |
Oerth Bio LLC |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115109055B
(zh)
*
|
2022-05-26 |
2023-11-28 |
北京康辰药业股份有限公司 |
一种用于egfr降解的双功能化合物及其应用
|
|
CN115160311B
(zh)
*
|
2022-05-26 |
2024-03-15 |
北京康辰药业股份有限公司 |
一种用于egfr降解的双功能化合物及其应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
CN115286643B
(zh)
*
|
2022-09-02 |
2023-09-01 |
南京大学 |
蛋白质靶向降解化合物及其制备方法和应用
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024073507A1
(en)
|
2022-09-28 |
2024-04-04 |
Theseus Pharmaceuticals, Inc. |
Macrocyclic compounds and uses thereof
|
|
WO2024086132A1
(en)
*
|
2022-10-17 |
2024-04-25 |
Ohio University |
Protacs targeting viral enzymes for precise treatment of covid-19
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|
|
CN119317636A
(zh)
*
|
2023-03-07 |
2025-01-14 |
艾博生物科技(上海)有限公司 |
编码活化EGFR突变肽的免疫调节治疗性mRNA组合物
|
|
WO2024246838A1
(en)
|
2023-05-31 |
2024-12-05 |
Beigene Switzerland Gmbh |
Compounds for the degradation of egfr kinase
|
|
WO2025006902A2
(en)
*
|
2023-06-29 |
2025-01-02 |
Dana-Farber Cancer Institute, Inc. |
Synthesis and in vitro characterization of proteolysis targeting chimeras (protacs) for degradation of dna methyltransferase 1 (dnmt1)
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025137613A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Ganymede Oncology, Inc. |
Cycloalkylene nrf2 protein degraders
|
|
WO2025235298A1
(en)
*
|
2024-05-07 |
2025-11-13 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway
|